MCID: ANG005
MIFTS: 55

Anogenital Venereal Wart

Categories: Gastrointestinal diseases, Infectious diseases, Oral diseases, Reproductive diseases, Skin diseases

Aliases & Classifications for Anogenital Venereal Wart

MalaCards integrated aliases for Anogenital Venereal Wart:

Name: Anogenital Venereal Wart 12 15 17
Genital Warts 12 54 42 3 15
Condylomata Acuminata 44 70
Condyloma Acuminatum 12 73
Anogenital Human Papilloma Virus Infectious Disease 12
Genital Wart Virus Infectious Disease 12
Anogenital Warts 12
Venereal Wart 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11168
ICD9CM 34 078.11
MeSH 44 D003218
NCIt 50 C2960 C4820
SNOMED-CT 67 240542006 302812006
ICD10 32 A63.0
UMLS 70 C0009663 C0554632

Summaries for Anogenital Venereal Wart

MedlinePlus : 42 Genital warts are a sexually transmitted disease (STD) caused by the human papillomavirus (HPV). The warts usually appear as a small bump or group of bumps in the genital area. They are flesh-colored and can be flat or look bumpy like cauliflower. Some genital warts are so small you cannot see them. In women, the warts usually occur in or around the vagina, on the cervix, or around the anus. In men, genital warts are less common. They may have warts on the tip of the penis, around the anus, or on the scrotum, thigh, or groin. You can get genital warts during oral, vaginal, or anal sex with an infected partner. Correct usage of latex condoms greatly reduces, but does not completely eliminate, the risk of catching or spreading HPV. If your or your partner is allergic to latex, you can use polyurethane condoms. The most reliable way to avoid infection is to not have anal, vaginal, or oral sex. HPV vaccines may help prevent some of the HPV infections that cause genital warts. Your health care provider usually diagnoses genital warts by seeing them. The warts might disappear on their own. If not, your health care provider can treat or remove them. HPV stays in your body even after treatment, so warts can come back. Dept. of Health and Human Services Office on Women's Health

MalaCards based summary : Anogenital Venereal Wart, also known as genital warts, is related to squamous cell papilloma and papilloma, and has symptoms including anogenital warts, fever and pruritus. An important gene associated with Anogenital Venereal Wart is IFNA1 (Interferon Alpha 1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Imiquimod and Catechin have been mentioned in the context of this disorder. Affiliated tissues include skin of vagina, cervix and skin, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A viral infectious disease that results in infection located in skin of vagina, cervix, uterus, anus, penis, scrotum, mouth, and throat, has material basis in human papillomaviruses (types 6 and 11), which are transmitted by direct contact with the skin during oral, genital, or anal sex with an infected partner. The infection has symptom anogenital warts.

CDC : 3 HPV is a common virus that can lead to certain types of cancer later in life. Getting your 11-12 year-old child two doses of the HPV vaccine can prevent these cancers.

Wikipedia : 73 Genital warts are a sexually transmitted infection caused by certain types of human papillomavirus... more...

Related Diseases for Anogenital Venereal Wart

Diseases related to Anogenital Venereal Wart via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 562)
# Related Disease Score Top Affiliating Genes
1 squamous cell papilloma 31.4 TP53 GP5 CDKN2A
2 papilloma 31.3 UBE3A TP53 CDKN2A CD4
3 in situ carcinoma 31.2 TP53 H2AC18 CDKN2A
4 syphilis 31.0 CD8A CD4 CCR6
5 cervix uteri carcinoma in situ 30.9 TP53 GP6 GP5 CDKN2A
6 genital herpes 30.9 CD8A CD4 CCR6
7 vulvar intraepithelial neoplasia 30.8 TP53 CDKN2A
8 herpes simplex 30.7 TLR9 TLR3 IFNB1 IFNA1
9 inverted follicular keratosis 30.7 GP6 GP5
10 penile cancer 30.7 TP53 GP5 CDKN2A
11 latent syphilis 30.6 CD8A CD4
12 primary syphilis 30.5 CD8A CD4
13 penile benign neoplasm 30.5 TP53 GP5 CDKN2A
14 vulva squamous cell carcinoma 30.5 TP53 GP5 CDKN2A
15 poliomyelitis 30.4 TLR3 IFNA1 CD8A CD4
16 systemic scleroderma 30.4 H2AC18 CD8A CD4 CCR6
17 urethritis 30.4 TLR4 CD8A CD4
18 mumps 30.4 TLR3 IL2 IFNB1 IFNA1
19 vulva cancer 30.4 TP53 GP5 CDKN2A
20 suppressor of tumorigenicity 3 30.4 UBE3A TP53 CDKN2A
21 chronic cervicitis 30.4 TP53 GP6 GP5 CDKN2A
22 cellulitis 30.3 CD8A CD4 CCR6
23 human papillomavirus infectious disease 30.3 TP53 IFNB1 CDKN2A
24 acute cystitis 30.3 TLR4 H2AC18 CD4 CCR6
25 vitiligo-associated multiple autoimmune disease susceptibility 1 30.3 IL2 CD8A CD4 CCR6
26 vulvar disease 30.3 TP53 GP5 CDKN2A CD4
27 pelvic inflammatory disease 30.3 TLR4 IL2 H2AC18
28 vulvovaginal candidiasis 30.3 IL2 IFNA1 CCR6
29 lymphangioma 30.2 TP53 IFNA2 H2AC18 CCR6
30 hepatitis a 30.2 TLR4 TLR3 IFNA1 CD4
31 vaginal cancer 30.2 UBE3A TP53 GP5 CDKN2A CD4
32 rubella 30.2 TLR4 TLR3 IL2 IFNB1
33 panuveitis 30.1 IFNA2 CD8A CD4 CCR6
34 crohn's disease 30.1 TLR9 TLR4 IL2 CD4 CCR6
35 contact dermatitis 30.0 TLR4 IL2 CD4 CCR6
36 cervix carcinoma 30.0 TP53 H2AC18 GP5 CDKN2A CCR6
37 dermatitis 30.0 TLR9 IL2 CD8A CD4 CCR6
38 vaccinia 30.0 TP53 IL2 IFNB1 IFNA1
39 deficiency anemia 30.0 IFNA2 IFNA1 H2AC18 CD8A CD4 CCR6
40 skin disease 29.9 TP53 TLR7 IL2 IFNA1 H2AC18 CD8A
41 kaposi sarcoma 29.9 TP53 IFNB1 IFNA2 IFNA1
42 epidermodysplasia verruciformis 1 29.9 UBE3A TP53 GP6 GP5 CD8A CD4
43 influenza 29.9 TLR7 TLR3 MYD88 IFNB1 IFNA1
44 acquired immunodeficiency syndrome 29.9 TP53 IL2 IFNA2 IFNA1 CD4 CCR6
45 dermatitis, atopic 29.9 TLR9 TLR4 IL2 CD8A CD4 CCR6
46 diarrhea 29.8 TLR4 IL2 IFNB1 IFNA2 IFNA1
47 anus cancer 29.8 UBE3A TP53 H2AC18 GP6 GP5 CDKN2A
48 human immunodeficiency virus infectious disease 29.8 TLR9 TLR7 IL2 IFNA1 H2AC18 CD8A
49 leukemia, acute lymphoblastic 29.7 TP53 IL2 H2AC18 CDKN2A CD8A CD4
50 allergic disease 29.7 TLR9 TLR8 TLR7 TLR4 IL2 CCR6

Graphical network of the top 20 diseases related to Anogenital Venereal Wart:



Diseases related to Anogenital Venereal Wart

Symptoms & Phenotypes for Anogenital Venereal Wart

Symptoms:

12
  • anogenital warts

UMLS symptoms related to Anogenital Venereal Wart:


fever; pruritus; pelvic pain; penile warts

MGI Mouse Phenotypes related to Anogenital Venereal Wart:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CCR6 CD4 CD8A CDKN2A GP6 IFNB1
2 homeostasis/metabolism MP:0005376 10.2 CCR6 CD4 CDKN2A GP5 GP6 IFNB1
3 immune system MP:0005387 10.1 CCR6 CD4 CD8A CDKN2A GP6 IFNB1
4 neoplasm MP:0002006 9.7 CDKN2A IFNB1 IL2 MYD88 TLR3 TLR4
5 no phenotypic analysis MP:0003012 9.5 CD4 CDKN2A IFNB1 IL2 MYD88 TP53
6 renal/urinary system MP:0005367 9.23 CD8A MYD88 RCN2 TLR4 TLR7 TLR8

Drugs & Therapeutics for Anogenital Venereal Wart

Drugs for Anogenital Venereal Wart (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
2
Catechin Approved, Withdrawn Phase 4 154-23-4 9064
3
Cantharidin Approved, Investigational Phase 4 56-25-7
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Epicatechin Investigational Phase 4 490-46-0 72276
6 Immunologic Factors Phase 4
7 Adjuvants, Immunologic Phase 4
8 interferons Phase 4
9 Tea Phase 4
10
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
11
Podophyllin Approved Phase 3 9000-55-9
12
Petrolatum Approved, Investigational Phase 3 8009-03-8
13 Vaccines Phase 3
14 Tubulin Modulators Phase 3
15 Antimitotic Agents Phase 3
16 Podophyllotoxin Phase 3 518-28-5
17 Immunosuppressive Agents Phase 3
18 Antirheumatic Agents Phase 3
19 Alkylating Agents Phase 3
20 insulin Phase 3
21 Dermatologic Agents Phase 3
22 Keratolytic Agents Phase 3
23 Insulin, Globin Zinc Phase 3
24
Sodium citrate Approved, Investigational Phase 2 68-04-2
25
Nitric Oxide Approved Phase 2 10102-43-9 145068
26
Coal tar Approved Phase 2 8007-45-2
27
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
28
Ranpirnase Investigational Phase 1, Phase 2 196488-72-9
29 Citrate Phase 2
30 Anticoagulants Phase 2
31 Chelating Agents Phase 2
32 Calcium, Dietary Phase 2
33 Pharmaceutical Solutions Phase 1, Phase 2
34 Protective Agents Phase 1, Phase 2
35 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 1, Phase 2
36 Radiation-Protective Agents Phase 1, Phase 2
37 Antiviral Agents Phase 1, Phase 2
38 Anti-Infective Agents Phase 1, Phase 2
39
Calcium Nutraceutical Phase 2 7440-70-2 271
40
Cidofovir Approved Phase 1 113852-37-2 60613
41
Formaldehyde Approved, Vet_approved 50-00-0 712
42
Aminolevulinic acid Approved 106-60-5 137
43 Contraceptive Agents
44 Photosensitizing Agents
45 Hematinics
46 Cola
47 Liver Extracts

Interventional clinical trials:

(show top 50) (show all 86)
# Name Status NCT ID Phase Drugs
1 Multicenter, Randomised, Double-blind, Vehicle-controlled Study Comparing Recurrence Rate Following Imiquimod 5% Cream or Vehicle 3 Times Per Week for 4 Weeks Prior to Ablative Therapy in Subjects Suffering From External Ano-Genital Warts Completed NCT00189293 Phase 4 Imiquimod
2 An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage Completed NCT01082302 Phase 4 Polyphenon E (Veregen) 15% ointment
3 Trichloroacetic Acid Versus Cantharone for the Treatment of Perenial Warts Completed NCT03625960 Phase 4 Cantharidin;Trichloroacetic Acid
4 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
5 A Randomized Controlled Trial to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts Terminated NCT01468636 Phase 4 Oral Zinc;Placebo
6 Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place Unknown status NCT03296397 Phase 3
7 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
8 An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men Completed NCT00090285 Phase 3
9 A Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00735462 Phase 3 2.5% imiquimod cream;3.75% imiquimod cream;Placebo cream
10 A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts Completed NCT00674739 Phase 3 Imiquimod;3.75% imiquimod cream;placebo cream
11 Evaluation of Safety and Immunogenicity of GARDASIL™ in Healthy Females Between 9 and 26 Years of Age in SubSaharan Africa Completed NCT01245764 Phase 3
12 A Randomized, Double-Blind, Three-Arm Parallel-Group, Placebo-Controlled Phase 3 Trial to Investigate the Clinical Efficacy and Safety of Polyphenon E in the Treatment of External Genital Warts Completed NCT00449982 Phase 3 Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
13 Efficacy of Glizigen-Viudid in the Treatment of External Anogenital Warts in Children and Adolescents. Completed NCT01111344 Phase 3
14 A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts. Completed NCT03532776 Phase 3 Podofilox Gel 0.5%;Condylox Topical Gel 0.5%;Placebo Gel
15 A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women Completed NCT01651949 Phase 3
16 Phase III Study of the Treatment of Genital Warts by Low Dose Cyclophosphamide Completed NCT00999986 Phase 3 cyclophosphamide
17 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
18 An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds) Completed NCT03158220 Phase 3
19 Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Completed NCT00092482 Phase 3
20 A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine Completed NCT00501137 Phase 3
21 A Study to Demonstrate Immunogenicity and Tolerability of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Preadolescents, and To Determine End-Expiry Specifications for the Vaccine Completed NCT00092495 Phase 3
22 A Phase III, Randomized, International, Placebo-Controlled, Double-Blind Clinical Trial to Study the Tolerability and Immunogenicity of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Given to Females 12-26 Years of Age Who Have Previously Received GARDASIL™ Completed NCT01047345 Phase 3
23 Immunogenicity and Safety of Quadrivalent HPV L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year-Old Women When Administered Alone or Concomitantly With Hepatitis B Vaccine (Recombinant)--the F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease Completed NCT00517309 Phase 3
24 A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered to 16- to 26- Year-Old Women Completed NCT00543543 Phase 3
25 Betaglucin 0.2% Gel Versus Imiquimod Cream 5% in the Treatment of Anogenital Warts in 102 Individuals Older Than 18 Years. Recruiting NCT03901690 Phase 3 Betaglucin soluble gel 0.2%;Imiquimod 5% cream
26 Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts Recruiting NCT02750202 Phase 3
27 A Randomized, Double-Blind and Positive-Controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) and 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04425291 Phase 3
28 A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age. Recruiting NCT04635423 Phase 3
29 A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years Recruiting NCT04422366 Phase 3
30 A Multicenter, Randomized, Double-Blind, Controlled (Bivalent Human Papillomavirus Vaccine (16,18 Type)(E. Coli)) Phase III Clinical Trial to Estimate Efficacy, Immunogenicity and Safty of the Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type) (E.Coli) in Healthy Women Aged 18 to 45 Years Active, not recruiting NCT04537156 Phase 3
31 A Randomized, Worldwide, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Immunogenicity, and Efficacy on the Incidence of HPV 16/18-Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 23-Year Old Women - The FUTURE II Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease) Active, not recruiting NCT00092534 Phase 3
32 The Efficacy of Intralesional Measles, Mumps, Rubella (MMR) Vaccine, Intralesional Candidal Antigen and Topical Podophyllin in Treatment of Genital Warts: A Comparative Study Not yet recruiting NCT03853785 Phase 3 Topical Podophyllin
33 Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma Terminated NCT01639638 Phase 2, Phase 3 PROAPOPTOTIC PEPTIDE CIGB 300
34 A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects Unknown status NCT03158974 Phase 2 VIR007
35 A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts. Unknown status NCT01943630 Phase 2 15% AS101 gel;Vehicle
36 A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts Completed NCT02015260 Phase 2 Topical NO;Placebo
37 A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts Completed NCT02462187 Phase 2 NVN1000 8% Gel;NVN1000 16%;Vehicle;NVN1000 24%
38 A Phase 2, Double-Blind, Placebo-Controlled Study to Determine the Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects With External Genital Warts Completed NCT03981822 Phase 2
39 A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts Completed NCT02849262 Phase 2 Omiganan (CLS001) topical gel;Vehicle topical gel
40 Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV Completed NCT02535104 Phase 1, Phase 2 Ranpirnase;Vehicle
41 Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts Completed NCT02377999 Phase 2 Picato
42 A Phase I/II, Open Labeled, Uncontrolled, Single Center Study of Topical AS101 for External Genital Warts Completed NCT01555112 Phase 1, Phase 2 Topical AS101
43 A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs) Completed NCT02482428 Phase 2 Investigational Treatment;Aldara
44 A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs) Completed NCT01796821 Phase 2 Vehicle gel;SR-T100 gel with 1.0 % SM;SR-T100 gel with 2.3% SM
45 A Double-blind, Placebo Controlled, Randomized, Phase IIa Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Repeated Topical Applications Over 42 Days of AP611074 5% Gel in Condyloma Patients Completed NCT01532102 Phase 1, Phase 2 AP611074;Placebo
46 An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts Completed NCT00941811 Phase 2 Imiquimod
47 A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients Completed NCT02724254 Phase 2 AP611074 5% gel;AP611074 matching placebo
48 A Randomized, Double-Blinded, Tolerability and Immunogenicity Study of a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine Administered Concomitantly With GARDASIL to 16- to 26- Year-Old Women Completed NCT00551187 Phase 2
49 A Phase IIa Randomized, Double-Blind Controlled With Gardasil, Clinical Trial to Study theTolerability and Immunogenicity of V505 (a Multivalent Human Papilloma Virus [HPV] L1 Virus Like Particle [VLP] Vaccine) in Healthy 16 to 26 Year Old Women Completed NCT00520598 Phase 2 Comparator: V505 formulation 2;Comparator: V505 formulation 2
50 A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years Active, not recruiting NCT02710851 Phase 2

Search NIH Clinical Center for Anogenital Venereal Wart

Inferred drug relations via UMLS 70 / NDF-RT 51 :


imiquimod
Interferon Alfa-2b
Interferon Alfa-n3
podophyllin
PODOPHYLLIN PWDR

Cochrane evidence based reviews: condylomata acuminata

Genetic Tests for Anogenital Venereal Wart

Anatomical Context for Anogenital Venereal Wart

The Foundational Model of Anatomy Ontology organs/tissues related to Anogenital Venereal Wart:

19
Skin Of Vagina

MalaCards organs/tissues related to Anogenital Venereal Wart:

40
Cervix, Skin, Uterus, Liver, Prostate, Thymus, T Cells

Publications for Anogenital Venereal Wart

Articles related to Anogenital Venereal Wart:

(show top 50) (show all 2396)
# Title Authors PMID Year
1
Challenge of reflectance confocal microscopy in the diagnosis of genital warts. 42 61
33053543 2020
2
Risk factors of HIV infection among female entertainment workers in Cambodia: Findings of a national survey. 61 42
33347494 2020
3
Time-trend of hospitalizations for anogenital warts in Veneto region in the HPV vaccination era: a cross sectional study (2007-2018). 42
33208109 2020
4
Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. 61 54
10512792 1999
5
Therapeutic approaches to papillomavirus infections. 61 54
9098642 1997
6
Intralesional beta-interferon treatment of cervical intraepithelial neoplasia associated with human papillomavirus infection. 54 61
8016908 1994
7
The effects of vitamin B12, vitamin D, ferritin level, neutrophil/monocyte ratio and some blood parameters on genital warts presence, the number of lesions, and recurrence rates. 61
33550671 2021
8
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018. 61
33492104 2021
9
[The consensus of the Portuguese Society of Andrology, Sexual Medicine and Reproduction on Male HPV: diagnosis]. 61
32565166 2021
10
College males' behaviors, intentions, and influencing factors related to vaccinating against HPV. 61
33054675 2021
11
Long-term relapse-free treatment with endoscopic submucosal dissection combined with magnifying narrow-band imaging for a pregnant patient with flat-type condyloma acuminatum: a case report. 61
33394332 2021
12
The place of 5-aminolaevulinic acid-photodynamic therapy in the treatment landscape of urethral warts: A systematic review. 61
33529745 2021
13
High-risk sexual behavior and HIV/STDs cascade of care in migrants: results from an Italian dedicated outpatient clinic. 61
33690214 2021
14
Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: What's ongoing, what's needed? 61
33678229 2021
15
--Human papillomavirus and Chinese international students in the United States: attitudes, knowledge, vaccination trends, healthcare behaviors, and sexual activity. 61
33705223 2021
16
5-Aminolevulinic photodynamic therapy versus carbon dioxide laser therapy for small genital warts: A multicenter, randomized, open-label trial. 61
31374308 2021
17
Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. 61
33705382 2021
18
Vulvovaginal candidiasis in Iran: A systematic review and meta-analysis on the epidemiology, clinical manifestations, demographic characteristics, risk factors, etiologic agents and laboratory diagnosis. 61
33741400 2021
19
Regulation of autophagy by high- and low-risk human papillomaviruses. 61
33590566 2021
20
The Effect of Indian Fig Fruit Extract on Human Papilloma Virus containing Cervical Cancer Cells (HeLa) by Decreasing the HPV18 L1 Gene Load. 61
33773542 2021
21
Utility of the Human Papillomavirus Vaccination in Management of HPV-associated Cutaneous Lesions. 61
33769773 2021
22
Correlation of the ALA-PDT Treatment Efficacy and the HPV Genotype Profile of Genital Warts after Cryotherapy Failure and Podophyllotoxin Therapy in Male Patients. 61
33672889 2021
23
Two Web-Based and Theory-Based Interventions With and Without Brief Motivational Interviewing in the Promotion of Human Papillomavirus Vaccination Among Chinese Men Who Have Sex With Men: Randomized Controlled Trial. 61
33528372 2021
24
Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. 61
33427033 2021
25
Public health impact and cost-effectiveness of a nine-valent gender-neutral HPV vaccination program in France. 61
33261895 2021
26
Clinical profile and co-infections of urethritis in males. 61
33423450 2021
27
Laser therapy in cutaneous and genital warts: A review article. 61
33314577 2021
28
Quantifying the under-reporting of uncorrelated longitudal data: the genital warts example. 61
33407173 2021
29
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata. 61
33613232 2021
30
Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature. 61
32990395 2021
31
Distribution of the most common types of HPV in Iranian women with and without cervical cancer. 61
32957835 2021
32
The epidemiologic and economic impact of a quadrivalent human papillomavirus vaccine in Thailand. 61
33571186 2021
33
Atypical presentation of genital molluscum contagiosum mimicking genital warts. 61
32438855 2020
34
Topical and Systemic Retinoids for the Treatment of Genital Warts: A Systematic Review and Meta-Analysis. 61
33279886 2020
35
Evaluation of a Serious Video Game to Facilitate Conversations About Human Papillomavirus Vaccination for Preteens: Pilot Randomized Controlled Trial. 61
33270028 2020
36
Acquired lymphangiectasia: a rare mimic of genital warts. 61
33423429 2020
37
Self-efficacy and HPV Vaccine Attitudes Mediate the Relationship Between Social Norms and Intentions to Receive the HPV Vaccine Among College Students. 61
32418009 2020
38
Real-world effectiveness of Human Papillomavirus vaccination against vulvovaginal high-grade precancerous lesions and cancers. 61
33377930 2020
39
The influence of affect on HPV vaccine decision making in an HPV vaccine naïve college student population. 61
32983851 2020
40
Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. 61
32659510 2020
41
A dual and conflicting role for imiquimod in inflammation: A TLR7 agonist and a cAMP phosphodiesterase inhibitor. 61
32828805 2020
42
Non-sexual HPV transmission and role of vaccination for a better future (Review). 61
33101476 2020
43
Perianal warts as a risk marker for anal high-risk-human papillomavirus (HPV) detection and HPV-associated diseases. 61
32713086 2020
44
HPVomics: An integrated resource for the human papillomavirus epitome and therapeutics. 61
32871223 2020
45
Analysis of dermatologic conditions in Turkey and Italy by using Google Trends analysis in the era of the COVID-19 pandemic. 61
32614116 2020
46
HPV11E7 inhibits IMQ-induced chemokine and colony-stimulating factor production in keratinocytes. 61
32739587 2020
47
Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated Diseases. 61
33019516 2020
48
Buschke-Loewenstein Tumor: A Case Report and Advocacy for Human Papillomavirus Vaccination. 61
33154856 2020
49
Gender differences in risk taking behaviors for Chlamydia trachomatis. 61
32701401 2020
50
One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study. 61
33048118 2020

Variations for Anogenital Venereal Wart

Expression for Anogenital Venereal Wart

Search GEO for disease gene expression data for Anogenital Venereal Wart.

Pathways for Anogenital Venereal Wart

Pathways related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 UBE3A TP53 TLR9 TLR8 TLR7 TLR4
2
Show member pathways
13.67 UBE3A TP53 TLR4 IL2 IFNB1 IFNA2
3
Show member pathways
13.44 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
4
Show member pathways
13.34 TP53 MYD88 IL2 IFNB1 IFNA2 IFNA1
5
Show member pathways
13.3 TP53 IL2 IFNB1 IFNA2 IFNA1 GP6
6
Show member pathways
13.23 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
7
Show member pathways
13.1 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
8
Show member pathways
13.02 UBE3A TP53 TLR4 TLR3 IL2 IFNB1
9
Show member pathways
12.93 TP53 TLR4 TLR3 MYD88 IFNB1 IFNA2
10 12.85 TP53 TLR9 TLR3 MYD88 IFNB1 IFNA2
11
Show member pathways
12.83 IL2 IFNA2 IFNA1 CD8A CD4
12
Show member pathways
12.74 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
13
Show member pathways
12.64 TLR9 TLR4 MYD88 IL2 CD8A CD4
14
Show member pathways
12.63 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
15
Show member pathways
12.61 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
16
Show member pathways
12.56 TP53 TLR9 TLR7 TLR4 TLR3 MYD88
17
Show member pathways
12.55 TLR3 MYD88 IFNB1 IFNA2 IFNA1
18 12.52 TLR9 TLR8 TLR7 TLR3 MYD88 IL2
19
Show member pathways
12.46 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
20
Show member pathways
12.39 IL2 IFNB1 IFNA2 IFNA1
21 12.38 TP53 TLR4 MYD88 IFNB1
22 12.32 TP53 IL2 CDKN2A CD4
23 12.29 TLR9 TLR4 MYD88 IFNB1 IFNA2 IFNA1
24 12.28 TLR4 MYD88 IFNB1 IFNA2 IFNA1
25
Show member pathways
12.28 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
26
Show member pathways
12.26 TP53 IL2 IFNB1 IFNA2 IFNA1
27
Show member pathways
12.24 TLR4 TLR3 IFNB1 IFNA2 IFNA1 H2AC18
28 12.22 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
29
Show member pathways
12.21 TLR9 TLR8 MYD88 IL2
30
Show member pathways
12.2 TLR9 TLR8 TLR7 TLR4 MYD88 IFNB1
31 12.15 TP53 IFNB1 IFNA2 IFNA1
32 12.11 TLR4 MYD88 IL2 IFNB1 CD8A CD4
33 12.06 IL2 IFNA2 GP5 CD8A CD4
34 11.89 TLR9 TLR8 TLR7 TLR4 TLR3
35
Show member pathways
11.89 TP53 TLR9 TLR8 TLR7 TLR4 TLR3
36
Show member pathways
11.87 TLR9 TLR8 TLR7 TLR4 TLR3 CD4
37 11.84 IL2 CD8A CD4 CCR6
38 11.67 TLR9 TLR4 CCR6
39 11.55 TP53 IL2 CDKN2A
40 11.54 TLR9 TLR4 MYD88
41 11.51 IFNB1 IFNA2 IFNA1
42
Show member pathways
11.38 TLR9 TLR8 TLR7 TLR4 TLR3 IL2
43 11.28 IL2 IFNB1 CD4
44 11.04 TLR9 TLR7 IL2 IFNB1 IFNA2 CD8A

GO Terms for Anogenital Venereal Wart

Cellular components related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.55 TLR8 TLR4 CD8A CD4 CCR6
2 endosome membrane GO:0010008 9.43 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
3 early phagosome GO:0032009 9.26 TLR9 TLR7
4 endolysosome membrane GO:0036020 8.92 TLR9 TLR8 TLR7 TLR3

Biological processes related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 UBE3A TP53 TLR9 TLR4 TLR3 IL2
3 immune system process GO:0002376 10.2 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
4 innate immune response GO:0045087 10.17 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
5 positive regulation of gene expression GO:0010628 10.14 TP53 TLR9 TLR4 TLR3 MYD88 CDKN2A
6 adaptive immune response GO:0002250 10.14 IL2 IFNB1 IFNA2 IFNA1 CD8A CD4
7 inflammatory response GO:0006954 10.12 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
8 cytokine-mediated signaling pathway GO:0019221 10.08 TP53 MYD88 IL2 IFNB1 IFNA2 IFNA1
9 cell surface receptor signaling pathway GO:0007166 10.07 MYD88 IFNB1 IFNA2 CD8A CD4
10 blood coagulation GO:0007596 10.02 IFNB1 IFNA2 IFNA1 GP6 GP5
11 defense response to virus GO:0051607 10.02 TLR9 TLR8 TLR7 TLR3 IFNB1 IFNA2
12 immune response GO:0006955 10.02 TLR9 TLR8 TLR7 TLR4 TLR3 IL2
13 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.01 TLR9 TLR4 TLR3 MYD88 CD4
14 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TLR9 TLR4 TLR3 MYD88
15 defense response GO:0006952 9.99 TLR3 IFNB1 IFNA2 IFNA1
16 response to virus GO:0009615 9.97 TLR8 TLR3 MYD88 IFNB1
17 positive regulation of inflammatory response GO:0050729 9.97 TLR9 TLR7 TLR4 TLR3 IL2
18 cellular response to mechanical stimulus GO:0071260 9.96 TLR8 TLR7 TLR4 TLR3 MYD88
19 positive regulation of tumor necrosis factor production GO:0032760 9.94 TLR9 TLR4 TLR3 MYD88
20 positive regulation of JNK cascade GO:0046330 9.93 TLR9 TLR4 TLR3 MYD88
21 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.92 TLR9 TLR8 TLR7 TLR4 TLR3
22 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TLR9 TLR7 TLR4 TLR3
23 type I interferon signaling pathway GO:0060337 9.9 MYD88 IFNB1 IFNA2 IFNA1
24 B cell differentiation GO:0030183 9.89 IFNB1 IFNA2 IFNA1
25 humoral immune response GO:0006959 9.89 IFNB1 IFNA2 IFNA1 CCR6
26 response to exogenous dsRNA GO:0043330 9.88 TLR3 IFNB1 IFNA2 IFNA1
27 positive regulation of interleukin-6 production GO:0032755 9.88 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
28 positive regulation of interleukin-12 production GO:0032735 9.86 TLR9 TLR4 TLR3
29 positive regulation of B cell proliferation GO:0030890 9.85 TLR9 TLR4 IL2
30 B cell proliferation GO:0042100 9.85 IFNB1 IFNA2 IFNA1
31 positive regulation of chemokine production GO:0032722 9.85 TLR9 TLR7 TLR4 TLR3 MYD88
32 microglial cell activation GO:0001774 9.84 TLR8 TLR7 TLR3
33 positive regulation of interferon-beta production GO:0032728 9.83 TLR9 TLR8 TLR7 TLR4 TLR3
34 T cell activation involved in immune response GO:0002286 9.82 IFNB1 IFNA2 IFNA1
35 necroptotic process GO:0070266 9.81 TP53 TLR4 TLR3
36 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.81 IFNB1 IFNA2 IFNA1
37 toll-like receptor 9 signaling pathway GO:0034162 9.81 TLR9 TLR8 TLR7 MYD88
38 natural killer cell activation involved in immune response GO:0002323 9.8 IFNB1 IFNA2 IFNA1
39 I-kappaB phosphorylation GO:0007252 9.8 TLR9 TLR7 TLR4 TLR3
40 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.72 TLR9 TLR8 TLR7 TLR4 MYD88
41 regulation of cytokine secretion GO:0050707 9.71 TLR9 TLR8
42 positive regulation of lymphocyte proliferation GO:0050671 9.71 TLR4 MYD88
43 enzyme linked receptor protein signaling pathway GO:0007167 9.71 GP6 CD4
44 negative regulation of T cell differentiation GO:0045581 9.7 IFNB1 IFNA2
45 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.7 TLR4 TLR3
46 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.69 IFNB1 IFNA2
47 positive regulation of toll-like receptor signaling pathway GO:0034123 9.68 TLR9 TLR3
48 regulation of dendritic cell cytokine production GO:0002730 9.65 TLR4 TLR3
49 positive regulation of interferon-alpha production GO:0032727 9.65 TLR9 TLR8 TLR7 TLR4 TLR3
50 positive regulation of interferon-gamma production GO:0032729 9.63 TLR9 TLR8 TLR7 TLR4 TLR3 IL2

Molecular functions related to Anogenital Venereal Wart according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.37 UBE3A TP53 TLR9 TLR8 TLR7 TLR4
2 cytokine activity GO:0005125 9.76 IL2 IFNB1 IFNA2 IFNA1
3 double-stranded RNA binding GO:0003725 9.61 TLR8 TLR7 TLR3
4 cytokine receptor binding GO:0005126 9.5 IFNB1 IFNA2 IFNA1
5 siRNA binding GO:0035197 9.48 TLR9 TLR7
6 type I interferon receptor binding GO:0005132 9.43 IFNB1 IFNA2 IFNA1
7 signaling receptor activity GO:0038023 9.43 TLR8 TLR4 TLR3 GP6 CD4 CCR6
8 MDM2/MDM4 family protein binding GO:0097371 9.4 TP53 CDKN2A
9 pattern recognition receptor activity GO:0038187 9.33 TLR9 TLR8 TLR7
10 transmembrane signaling receptor activity GO:0004888 9.17 TLR9 TLR8 TLR7 TLR4 TLR3 GP6

Sources for Anogenital Venereal Wart

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....